|
|
||||||||
CUTTING EDGE |




,
,
* Programs in M.D./Ph.D.,
Genetics Program, and
Immunology Program, and
Department of Pathology, Tufts University School of Medicine, Boston, MA 02111
EBV, a ubiquitous human herpesvirus, is the causative agent of infectious mononucleosis and is associated with many carcinomas. We have previously shown that the EBV latent genes LMP-1 and LMP-2A (for latent membrane proteins 1 and 2A), transactivate a human endogenous retrovirus (HERV), HERV-K18, in infected B lymphocytes. The envelope (Env) protein of HERV-K18 encodes a superantigen that strongly stimulates a large number of T cells. In this study we report that HERV-K18 env is transactivated even earlier in the infection process, before the establishment of latency; namely, we found that EBV, through its interaction with its cellular receptor CD21, induces the HERV-K18 env gene in resting B lymphocytes. This transactivation is direct and immediate, as up-regulation of transcripts can be detected within 30 min after EBV exposure. Thus, EBV binding to human CD21 on resting B cells triggers the expression of an endogenous superantigen. The biological significance of this superantigen expression for the EBV life cycle is discussed.
This article has been cited by other articles:
![]() |
C. Voisset, R. A. Weiss, and D. J. Griffiths Human RNA "Rumor" Viruses: the Search for Novel Human Retroviruses in Chronic Disease Microbiol. Mol. Biol. Rev., March 1, 2008; 72(1): 157 - 196. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Butler, N. Wertz, P. Weber, and K. M. Lager Porcine Reproductive and Respiratory Syndrome Virus Subverts Repertoire Development by Proliferation of Germline-Encoded B Cells of All Isotypes Bearing Hydrophobic Heavy Chain CDR3 J. Immunol., February 15, 2008; 180(4): 2347 - 2356. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Lunemann, T. Kamradt, R. Martin, and C. Munz Epstein-Barr Virus: Environmental Trigger of Multiple Sclerosis? J. Virol., July 1, 2007; 81(13): 6777 - 6784. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |